Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Yifan WuTao OuyangJinfeng LiTianfeng WangZhaoqing FanTie FanBenyao LinYe XuYuntao XiePublished in: Breast cancer research and treatment (2019)
PALB2 germline mutations are present at 0.71% in Chinese BRCA1/2-negative breast cancer patients and are more frequent in patients with triple-negative breast cancer and family histories of breast and/or ovarian cancer.
Keyphrases